{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:21:32Z","timestamp":1762899692079,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.euf.2018.10.010","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T17:58:59Z","timestamp":1541699939000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Building on a Solid Foundation: Enhancing Bacillus Calmette-Gu\u00e9rin Therapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Cyrill A.","family":"Rentsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-161X","authenticated-orcid":false,"given":"Laurent","family":"Derr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah G.","family":"Dugas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Wetterauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl R.","family":"Federer-Gsponer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6388-7003","authenticated-orcid":false,"given":"Molly A.","family":"Ingersoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.10.010_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0020","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0030","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Guerin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0035","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000353089","article-title":"Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center","volume":"92","author":"Lazica","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2018.10.010_bib0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.ju.0000070437.14275.e0","article-title":"Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study","volume":"170","author":"Grimm","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOU.0000000000000377","article-title":"Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype","volume":"27","author":"Herrmann","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0060","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1089\/end.2015.0336","article-title":"Thulium laser endoscopic en bloc enucleation of nonmuscle-invasive bladder cancer","volume":"29","author":"Migliari","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.euf.2018.10.010_bib0065","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0070","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2013.09.049","article-title":"Bacillus Calmette-Guerin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist\u2019s failure to detect urothelial carcinoma of the upper urinary tract and urethra","volume":"65","author":"Giannarini","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0075","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.10.010_bib0080","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/UA.UA_115_17","article-title":"Prognostic impact of Bacillus Calmette-Guerin interruption at the time of induction and consolidation","volume":"9","author":"Alhogbani","year":"2017","journal-title":"Urol Ann"},{"key":"10.1016\/j.euf.2018.10.010_bib0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q","article-title":"The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies","volume":"89","author":"Zeegers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2018.10.010_bib0100","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.eururo.2012.08.025","article-title":"Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer","volume":"63","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0105","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.juro.2010.06.140","article-title":"Smoking cessation assistance for patients with bladder cancer: a national survey of American urologists","volume":"184","author":"Bjurlin","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.euf.2018.10.010_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1365-2249.2002.01734.x","article-title":"IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer","volume":"127","author":"Riemensberger","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0125","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.170.3963.1217","article-title":"Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG)","volume":"170","author":"Zbar","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.euf.2018.10.010_bib0130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0022-5347(17)42723-6","article-title":"Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer","volume":"139","author":"Torrence","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"Luftenegger","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.10.005","article-title":"Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy","volume":"36","author":"Niwa","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0150","first-page":"1","article-title":"[BCG vaccination in the world]","volume":"75","author":"Toida","year":"2000","journal-title":"Kekkaku"},{"issue":"2","key":"10.1016\/j.euf.2018.10.010_bib0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","article-title":"The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer","volume":"34","author":"Horn","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.02.018","article-title":"Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy","author":"Ornstein","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0165","doi-asserted-by":"crossref","first-page":"11450","DOI":"10.18632\/oncotarget.7199","article-title":"Frequency of CD4 + CD25 + Foxp3 + cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal","volume":"7","author":"J\u00f3\u017awicki","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2018.10.010_bib0170","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/1078-0432.CCR-04-1101","article-title":"Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer","volume":"11","author":"Gu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2018.10.010_bib0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder canc er","volume":"59","author":"Chiong","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0180","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guerin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.10.010_bib0185","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0195","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0205","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euf.2018.10.010_bib0210","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0215","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","article-title":"Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy","volume":"55","author":"Ayari","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0220","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette-Guerin: a long-term follow-up study of a Japanese cohort","volume":"18","author":"Miyake","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euf.2018.10.010_bib0225","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2018.10.010_bib0230","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euf.2018.10.010_bib0235","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euf.2018.10.010_bib0245","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MOU.0000000000000543","article-title":"Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology","volume":"28","author":"Dyrskjot","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0250","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2018.10.010_bib0255","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nrurol.2013.113","article-title":"Aberrant expression of microRNAs in bladder cancer","volume":"10","author":"Yoshino","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0260","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1038\/s41598-017-05801-3","article-title":"MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Xie","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2018.10.010_bib0265","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euf.2018.10.010_bib0270","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062483","article-title":"ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors","volume":"8","author":"Balbas-Martinez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2018.10.010_bib0280","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2012.05.050","article-title":"Polyamine-modulated factor-1 methylation predicts bacillus Calmette-Guerin response in patients with high-grade non-muscle-invasive bladder carcinoma","volume":"63","author":"Alvarez-Mugica","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euf.2018.10.010_bib0290","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.4111\/icu.2016.57.S1.S98","article-title":"Immune checkpoint blockade therapy for bladder cancer treatment","volume":"57","author":"Kim","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0295","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2018.10.010_bib0300","first-page":"9231","article-title":"Bacillus Calmette-Guerin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival","volume":"15","author":"Rahmat","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euf.2018.10.010_bib0305","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0310","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euf.2018.10.010_bib0315","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2014.04.008","article-title":"All bacillus Calmette-Guerin (BCG) strains are equal, but some BCG strains are more equal than others","volume":"66","author":"Noon","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0320","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.euf.2018.10.010_bib0335","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0340","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/01.ju.0000091826.83705.79","article-title":"Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response","volume":"170","author":"De Boer","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0345","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF01534428","article-title":"Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy","volume":"39","author":"McAveney","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euf.2018.10.010_bib0355","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0022-5347(05)67417-4","article-title":"Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2","volume":"164","author":"Yamada","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0360","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","article-title":"Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma","volume":"27","author":"Arnold","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.euf.2018.10.010_bib0365","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-009-0673-z","article-title":"Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euf.2018.10.010_bib0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","article-title":"Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity","volume":"137","author":"Luo","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0375","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","article-title":"Antitumor activity of recombinant bacille Calmette-Guerin secreting interleukin-15-Ag85B fusion protein against bladder cancer","volume":"35","author":"Takeuchi","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.euf.2018.10.010_bib0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/or.2015.3985","article-title":"Recombinant hIFN-\u03b12b-BCG inhibits tumor growth in a mouse model of bladder cancer","volume":"34","author":"Sun","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.euf.2018.10.010_bib0385","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0390","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0395","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euf.2018.10.010_bib0400","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.95.9.5299","article-title":"Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes","volume":"95","author":"Hess","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euf.2018.10.010_bib0405","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","article-title":"The recombinant tuberculosis vaccine rBCG \u0394ureC hly+ induces apoptotic vesicles for improved priming of CD4+ and CD8+ T cells","volume":"30","author":"Farinacci","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.euf.2018.10.010_bib0410","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","article-title":"Recombinant BCG \u0394ureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses","volume":"204","author":"Desel","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.euf.2018.10.010_bib0415","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/infdis\/jiu347","article-title":"Central memory CD4+ T cells are responsible for the recombinant bacillus Calmette-Guerin \u0394ureC:hly vaccine\u2019s superior protection against tuberculosis","volume":"210","author":"Vogelzang","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.euf.2018.10.010_bib0420","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.euf.2018.10.010_bib0425","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.10.010_bib0430","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","article-title":"Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer","volume":"48","author":"Stricker","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.euf.2018.10.010_bib0435","article-title":"Intravesical bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"2017","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2018.10.010_bib0440","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2018.10.010_bib0450","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.urolonc.2016.09.004","article-title":"Emerging role of checkpoint inhibition in localized bladder cancer","volume":"34","author":"Singh","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0455","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","article-title":"Role of immunotherapy in bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.10.010_bib0460","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2018.10.010_bib0465","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-16-1189","article-title":"Intravesical bacillus Calmette Guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients","volume":"23","author":"Derre","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:39Z","timestamp":1762498059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918303110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2405456918303110"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.10.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building on a Solid Foundation: Enhancing Bacillus Calmette-Gu\u00e9rin Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}